Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 – 9, 2024
SHELTON, Conn., April 2, 2024 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024. The conference is being held on April 8 – 9, 2024 at the Sofitel Hotel in New York City.